Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis
Безопасность симптоматических препаратов замедленного действия для лечения остеоартрита: результаты систематического обзора и метаанализа
2019-04-01
SCID: 54.1/eqnm66ut
Discuss with AI
SYSADOAsadverse eventsosteoarthritisrandom-effects meta-analysissystematic review
Figures from the paper
Abstract (AI)
Symptomatic slow-acting drugs for osteoarthritis (SYSADOAs) are an important drug class in the treatment armamentarium for osteoarthritis (OA). We aimed to re-assess the safety of various SYSADOAs in a comprehensive meta-analysis of randomized placebo-controlled trials, using, as much as possible, data from full safety reports. We performed a systematic review and random-effects meta-analyses of randomized, double-blind, placebo-controlled trials that assessed adverse events (AEs) with various SYSADOAs in patients with OA. The databases MEDLINE, Cochrane Central Register of Controlled Trials (Ovid CENTRAL) and Scopus were searched. The primary outcomes were overall severe and serious AEs, as well as AEs involving the following Medical Dictionary for Regulatory Activities (MedDRA) system organ classes (SOCs): gastrointestinal, cardiac, vascular, nervous system, skin and subcutaneous tissue, musculoskeletal and connective tissue, renal and urinary system. Database searches initially identified 3815 records. After exclusions according to the selection criteria, 25 studies on various SYSADOAs were included in the qualitative synthesis, and 13 studies with adequate data were included in the meta-analyses. Next, from the studies previously excluded according to the protocol, 37 with mainly oral nonsteroidal anti-inflammatory drugs (NSAIDs) permitted as concomitant medication were included in a parallel qualitative synthesis, from which 18 studies on various SYSADOAs were included in parallel meta-analyses. This post hoc parallel inclusion was conducted because of the high number of studies allowing concomitant anti-OA medications. Indeed, primarily excluding studies with concomitant anti-OA medications was crucial for a meta-analysis on safety. The decision for parallel inclusion was made for the purpose of comparative analyses. Glucosamine sulfate (GS), chondroitin sulfate (CS) and avocado soybean unsaponifiables (ASU; Piascledine ® ) were not associated with increased odds for any type of AEs compared with placebo. Overall, with/without concomitant OA medication, diacerein was associated with significantly increased odds of total AEs (odds ratio [OR] 2.22; 95% confidence interval [CI] 1.58–3.13; I 2 = 52.8%), gastrointestinal disorders (OR 2.85; 95% CI 2.02–4.04; I 2 = 62.8%) and renal and urinary disorders (OR 3.42; 95% CI 2.36–4.96; I 2 = 17.0%) compared with placebo. In studies that allowed concomitant OA medications, diacerein was associated with significantly more dermatological disorders (OR 2.47; 95% CI 1.42–4.31; I 2 = 0%) and more dropouts due to AEs (OR 3.18; 95% CI 1.85–5.47; I 2 = 13.4%) than was placebo. No significant increase in serious or severe AEs was found with diacerein versus placebo. GS and CS can be considered safe treatments for patients with OA. All eligible studies on ASU included in our analysis used the proprietary product Piascledine ® and allowed other anti-OA medications; thus, the safety of ASU must be confirmed in future studies without concomitant anti-OA medications. Given the safety concerns with diacerein, its usefulness in patients with OA should be assessed, taking into account individual patient characteristics.
Key Findings
1
A parallel post hoc analysis included studies permitting mainly oral NSAIDs as concomitant medication to enable comparative safety assessment despite potential confounding.
2
Searches identified 3815 records; 25 studies were included in qualitative synthesis, while 13 with adequate data entered the primary meta-analyses.
3
The abstract reports that glucosamine sulfate, chondroitin sulfate, and avocado soybean unsaponifiables were not associated with an increase in adverse events; the sentence is truncated before further results are provided.
4
The primary safety outcomes were severe and serious adverse events and adverse events across gastrointestinal, cardiac, vascular, nervous, skin, musculoskeletal, and renal/urinary systems.
5
The systematic review evaluated adverse events associated with symptomatic slow-acting drugs for osteoarthritis in randomized, double-blind, placebo-controlled trials.
Research Object
Symptomatic slow-acting drugs for osteoarthritis (SYSADOAs) in patients with osteoarthritis
Research Subject
Safety outcomes, particularly severe and serious adverse events and system organ class-specific adverse events, associated with SYSADOAs
Publication Details
Publication Date
2019-04-01
Journal
Publisher
ISSN
Cited by
116
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai5
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement2009
Bias in meta-analysis detected by a simple, graphical test1997
The “Golden Age” of Probiotics: A Systematic Review and Meta-Analysis of Randomized and Observational Studies in Preterm Infants2017
American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee2012
An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)2014
Cited by4
An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)2019
Efficacy of combined use of glycosaminoglycan peptide complex for intramuscular administration and oral diacerein in osteoarthritis: evaluation according to an observational multicenter clinical trial2021
Outcomes of the use of the glycosaminoglycan-peptide complex as monotherapy and in combination with diacerein for the treatment of knee osteoarthritis in real-world practice2023
EFFECTIVENESS AND SAFETY OF CONCOMITANT USE OF PEPTIDE COMPLEX AND DIACEREIN IN OSTEOARTHRITIS OF KNEE JOINT2022